Clin Mol Hepatol > Volume 27(4); 2021 > Article |
|
Study | Outcome | No. | Metabolites (panel) | Performance | |
---|---|---|---|---|---|
Lipid | |||||
Zhou et al. [6] (2016) | Non-NASH vs. NASH | Estimation, n=223 (non-NASH, n=176; NASH, n=47) | NASH ClinLipMet Score (glutamate, isoleucine, glycine, lysophosphatidylcholine 16:0, phosphoethanolamine 40:6, AST, fasting insulin, PNPLA3 genotype) | AUROC, 0.866; sensitivity, 86%; specificity, 72% | |
Validation, n=95 (non-NASH, n=71; NASH, n=24) | |||||
Mayo et al. [7] (2018) | NAFL vs. NASH | Discovery, n=467 (control, n=90; NAFL, n=246; NASH, n=131) | 20 triglyceride species and BMI | AUROC, 0.95; sensitivity, 83%; specificity, 94% | |
Validation, n=192 (control, n=7; NAFL, n=109; NASH, n=76) | |||||
Barr et al. [8] (2012) | NAFL vs. NASH | Discovery (n=374) | BMI-dependent metabolic profile of 292 metabolites and 51 unidentified variables | AUROC, 0.84; sensitivity, 62%; specificity, 97% | |
Validation (n=93) | |||||
Bril et al. [9] (2018) | NAFL vs. NASH | 220 (no NAFLD, n=66; NAFL, n=39; NASH, n=115) | 20 triglyceride species and BMI | AUROC, 0.69 | |
Caussy et al. [12] (2019) | F0–F2 vs. F3–F4 | Derivation, n=156 (F0–F2, n=133; F3–F4, n=23) | 8 lipids (5alpha-androstan-3beta monosulfate, pregnanediol-3-glucuronide, androsterone sulfate, epiandrosterone sulfate, palmitoleate, dehydroisoandrosterone sulfate, 5alphaandrostan-3beta disulfate, glycocholate), taurine, fucose | AUROC, 0.94; sensitivity, 90%; specificity, 79% | |
Validation 1, n=142 (MRE <3.63 kPa, n=131; MRE ≥3.6 kPa, n=11) | |||||
Validation 2 (n=59) | |||||
Caussy et al. [13] (2020) | F0–F2 vs. F3–F4 | 427 (F0–2, n=229; F3–F4, n=197) | Baseline (11,12-DIHETE, tetranor 12-HETE, adrenic acid, and 14, 15-DIHETE), ≥1 stage improvement in fibrosis at 24-week follow-up (5-HETE, 7,17-DHDPA, adrenic acid, arachidonic acid, eicosapentaenoic acid, 16-HDOHE, and 9-HODE) | AUROC, 0.74 (follow-up) | |
Perakakis et al. [14] (2019) | F0 vs. F1–F4 | 80 (control, n=49; NAFL, n=15; NASH, n=16) | 10 lipids, 5 glycans, 5 fatty acids | AUROC, 1.0; sensitivity, 97%; specificity, 99% | |
Ogawa et al. [15] (2020) | Hepatocellular ballooning | 132 (non-ballooning, n=83; ballooning, n=49) | Type IV collagen 7S, choline, LPE (e-18:2) | AUROC, 0.846; sensitivity, 89.4%; specificity, 71.4% | |
Amino acids | |||||
Gaggini et al. [20] (2018) | F0–F2 vs. F3–F4 | 64 (control, n=20; nonobese NAFLD, n=29; obese NAFLD, n=15) | Glutamate-serine-glycine index | OR, 122 (P=0.004) | |
Grzych et al. [25] (2020) | NAFL vs. NASH vs. NASH cirrhosis | Discovery, n=213 (control, n=69; NAFL, n=78; NASH, n=23; NASH cirrhosis, n=15; non-NASH cirrhosis, n=28) | Glycocholic acid, taurocholic acid, phenylalanine, branched-chain amino-acids | Accuracy, 94.0%; sensitivity, 94.1%; specificity, 93.8% | |
Validation, n=94 (control, n=44; NAFL, n=34; NASH, n=10; NASH-cirrhosis, n=6) | |||||
Bile acid | |||||
Legry et al. [29] (2017) | Advanced fibrosis, NASH, hepatocellular ballooning | 152 (control, n=50; NAFLD, n=102) | Keto-deoxycholic acid, 7-ketolithocholic acid | Keto-deoxycholic acid with advanced fibrosis (OR, 4.2), NASH (OR, 24.5) and hepatocellular ballooning (OR, 18.7); 7-ketolithocholic acid with NASH (OR, 9.4) and ballooning (OR, 5.9) |
F0–F4 represents the stage of hepatic fibrosis on a scale from 0 to 4.
NAFL, nonalcoholic fatty liver; NASH, nonalcoholic steatohepatitis; AST, aspartate aminotransferase; PNPLA3, patatin-like phospholipase domaincontaining-3; AUROC, area under the receiver operating characteristic; BMI, body mass index; NAFLD, nonalcoholic fatty liver disease; MRE, magnetic resonance elastography; DIHETE, dihydroxy-5Z,8Z,14Z,17Z-eicosatetraenoic acid; HETE, hydroxyeicosatetraenoic acid; DHDPA, dihydroxy-(8Z,10,13,15E,19Z)-docosapentaenoic acid; HDOHE, hydroxy-docosahexaenoic acid; HODE, hydroxy-octadecadienoic acid; LPE, lysophosphatidylethanolamine; OR, odds ratio.